



WHITE DIAMOND
RESEARCH

THE CLOCK IS TICKING FOR NYMOX PHARMA'S EUROPEAN DRUG APPLICATION – BET ON A REJECTION

February 1, 2018



WHITE DIAMOND
RESEARCH

RESEARCH SUMMARY

Nymox drug, fexapotide, to treat enlarged prostate, is about to have its marketing application decided in Europe within a few months, and we're betting on a rejection.

Nymox did two phase 3 trials for fexapotide in the US with a total of 1,000 patients testing throughout one year. Both trials failed to show improvement over placebo.

Years after the phase 3 trials, Nymox reported follow-up studies with positive data to those trials, but evidence shows it is unreliable data.

For Nymox's follow-up studies, there was no independent verification party, no pre-specified endpoints, and it's unlikely that a drug's efficacy would take effect years later, after having no effect at one year.

Nymox switched from trying to get approval in the US to Europe, but recent events show Europe might actually be tougher to get approval.

Nymox drug, fexapotide, to treat enlarged prostate, is about to have its marketing application decided in Europe within a few months, and we're betting on a rejection.

Nymox did two phase 3 trials for fexapotide in the US with a total of 1,000 patients testing throughout one year. Both trials failed to show improvement over placebo.

Years after the phase 3 trials, Nymox reported follow-up studies with positive data to those trials, but evidence shows it is unreliable data.

For Nymox's follow-up studies, there was no independent verification party, no pre-specified endpoints, and it's unlikely that a drug's efficacy would take effect years later, after having no effect at one year.

Nymox switched from trying to get approval in the US to Europe, but recent events show Europe might actually be tougher to get approval.

Read full report on Seeking Alpha [here](#).

Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC